When immune landscapes diverge: How immune cell heterogeneity shapes cancer immunotherapy response
Open Access
- 10 July 2026
- journal article
- Published by Pivot Science Publications Corporation in Cancer Heterogeneity and Plasticity
- Vol. 3 (3)
Abstract
Amplifying the antitumor immune response using immunotherapy has significantly improved patient survival and transformed cancer care. Findings from preclinical studies as well as clinical observations have firmly established that the intratumoral accumulation of T cells often serves as a positive predictor of immunotherapy response. While this observation has led to the commonly used “cold or hot” classifiers to describe the T cell landscape within a tumor, this is increasingly being recognized as an oversimplification. Instead, there is a growing appreciation for the broader composition, spatial localization, and dynamic nature of the tumor immune landscape across cancer types. In this perspective, we describe the diverse and unique immune correlates that have been associated with response (or lack thereof) following immunotherapy. Beginning with our own published findings related to the heterogeneous immune landscapes associated with divergent responses to adoptive T cell therapy combined with immune checkpoint inhibition, we then overlay key observations from other recently published studies to highlight the impact of the broader immune landscape in determining treatment outcome. Finally, we recommend leveraging modern multi-omic analysis tools prior to and during immunotherapy treatment to define immune signatures associated with favorable response, those that can predict treatment outcome, or which can be leveraged to identify complementary therapeutic approaches.Keywords
This publication has 31 references indexed in Scilit:
- Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cellsCancer Cell, 2026
- IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunityCancer Cell, 2025
- IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacyImmunity, 2025
- Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancerCancer Cell, 2025
- Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structuresCell Reports Medicine, 2025
- Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: Advancing towards clinical applicationCancer Letters, 2025
- A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancerCancer Cell, 2025
- Tertiary lymphoid structures and cancer immunotherapy: From bench to bedsideMed, 2025
- Turning cold into hot: emerging strategies to fire up the tumor microenvironmentTrends in Cancer, 2024
- The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactionsCancer Cell, 2024